5‑fluorouracil enhances the antitumor effect of sorafenib and sunitinib in a xenograft model of human renal cell carcinoma

Miyake,Makito; Anai,Satoshi; Fujimoto,Kiyohide; Ohnishi,Sayuri; Kuwada,Masaomi; Nakai,Yasushi; Inoue,Takeshi; Tomioka,Atsushi; Tanaka,Nobumichi; Hirao,Yoshihiko

doi:10.3892/ol.2012.662

5‑fluorouracil enhances the antitumor effect of sorafenib and sunitinib in a xenograft model of human renal cell carcinoma

Authors:
- Makito Miyake
- Satoshi Anai
- Kiyohide Fujimoto
- Sayuri Ohnishi
- Masaomi Kuwada
- Yasushi Nakai
- Takeshi Inoue
- Atsushi Tomioka
- Nobumichi Tanaka
- Yoshihiko Hirao
View Affiliations

Affiliations: Department of Urology, Nara Medical University, Nara 634-8522, Japan
Published online on: March 29, 2012 https://doi.org/10.3892/ol.2012.662
Pages: 1195-1202

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Sorafenib and sunitinib are multi-kinase inhibitors with antitumor activity in patients with advanced renal cell carcinoma (RCC). Several studies have evaluated the effect of sorafenib/sunitinib in combination with chemotherapeutic agents in different types of tumor. However, few studies have addressed the activity of fluorinated pyrimidine in combination with sorafenib/sunitinib. In this study, we examined the potential of combination therapy with 5FU and sorafenib/sunitinib in human RCC cell lines. Three human RCC cell lines, ACHN, Caki‑1 and Caki‑2, were used to assess sensitivity to 5‑fluorouracil (5FU), sorafenib and sunitinib alone or in combination using an in vitro cell survival assay. Caki‑2 cells demonstrated significantly higher resistance to 5FU and sorafenib as compared to ACHN and Caki‑1. Additive antitumor effects of the combination therapy were observed in the in vitro study. There was a tendency for a positive correlation between the sensitivity to sunitinib and platelet-derived growth factor β (PDGFR‑β) expression levels, which were examined by reverse transcription polymerase chain reaction. Caki‑1 xenograft models were prepared by inoculating cells subcutaneously into nude mice, which were divided randomly into six groups: control, 5FU (8 mg/kg/day, intraperitoneally), sorafenib (15 mg/kg/day, orally), sunitinib (20 mg/kg/day, orally), and 5FU with sorafenib or sunitinib. The treatments were administered on 5 days each week, and tumor growth was monitored for 42 days following inoculation of cells. Synergistic antitumor effects of the combination therapy were observed in an in vivo study. The resected tumors were evaluated using the Ki‑67 labeling index and microvessel density. Both the Ki‑67 labeling index and microvessel density were decreased in tumors treated with the combination therapy compared to those treated with sorafenib/sunitinib alone. These findings suggest that the combination therapy of 5FU with sorafenib/sunitinib may be an effective therapeutic modality for advanced RCC patients.

View Figures

View References

1	Rini BI: Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions. Clin Cancer Res. 13:1098–1106. 2007. View Article : Google Scholar : PubMed/NCBI
2	Wagstaff J: Renal cell cancer: is immunotherapy dead? Ann Oncol. 18(Suppl 9): 94–97. 2007. View Article : Google Scholar : PubMed/NCBI
3	Ferrara N: Vascular endothelial growth factor as a target for anticancer therapy. Oncologist. 9(Suppl 1): 2–10. 2004. View Article : Google Scholar
4	Wilhelm SM, Carter C, Tang L, et al: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64:7099–7109. 2004. View Article : Google Scholar : PubMed/NCBI
5	Roskoski R Jr: Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. Biochem Biophys Res Commun. 356:323–328. 2007. View Article : Google Scholar : PubMed/NCBI
6	Hutson TE: Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence. Oncologist. 16(Suppl 2): 14–22. 2011. View Article : Google Scholar : PubMed/NCBI
7	Escudier B, Eisen T, Stadler WM, et al: Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol. 27:3312–3318. 2009. View Article : Google Scholar : PubMed/NCBI
8	Motzer RJ, Hutson TE, Tomczak P, et al: Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 27:3584–3590. 2009. View Article : Google Scholar : PubMed/NCBI
9	Dal Lago L, D’Hondt V and Awada A: Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumors. Oncologist. 13:845–858. 2008.PubMed/NCBI
10	Ulahannan SV and Brahmer JR: Antiangiogenic agents in combination with chemotherapy in patients with advanced non-small cell lung cancer. Cancer Invest. 29:325–337. 2011. View Article : Google Scholar : PubMed/NCBI
11	Sweeney CJ, Chiorean EG, Verschraegen CF, Lee FC, Jones S, Royce M, Tye L, Liau KF, Bello A, Chao R and Burris HA: A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors. J Clin Oncol. 28:4513–4520. 2010. View Article : Google Scholar : PubMed/NCBI
12	Castillo-Avila W, Piulats JM, Garcia Del Muro X, Vidal A, Condom E, Casanovas O, Mora J, Germà JR, Capellà G, Villanueva A and Viñals F: Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors. Clin Cancer Res. 15:3384–3395. 2009. View Article : Google Scholar
13	Zhang D, Hedlund EM, Lim S, Chen F, Zhang Y, Sun B and Cao Y: Antiangiogenic agents significantly improve survival in tumor-bearing mice by increasing tolerance to chemotherapy-induced toxicity. Proc Natl Acad Sci USA. 108:4117–4122. 2011. View Article : Google Scholar
14	Yoon CY, Lee JS, Kim BS, Jeong SJ, Hong SK, Byun SS and Lee SE: Sunitinib malate synergistically potentiates anti-tumor effect of gemcitabine in human bladder cancer cells. Korean J Urol. 52:55–63. 2011. View Article : Google Scholar : PubMed/NCBI
15	Hartmann JT and Bokemeyer C: Chemotherapy for renal cell carcinoma. Anticancer Res. 19:1541–1543. 1999.PubMed/NCBI
16	Ravaud A, Trufflandier N, Ferrière JM, Debled M, Palussière J, Cany L, Gaston R, Mathoulin-Pélissier S and Bui BN: Subcutaneous interleukin-2, interferon alpha-2b and 5-fluorouracil in metastatic renal cell carcinoma as second-line treatment after failure of previous immunotherapy: a phase II trial. Br J Cancer. 89:2213–2218. 2003. View Article : Google Scholar : PubMed/NCBI
17	Miyake M, Fujimoto K, Tanaka M, Hirao Y, Uemura H, Otani T and Yoshii M: Immunochemotherapy with interferon-α, interleukin-2, 5-fluorouracil, and cimetidine for patients with advanced renal cell carcinoma. J Nara Med Assoc. 60:37–47. 2009.
18	Naito S, Eto M, Shinohara N, Tomita Y, Fujisawa M, Namiki M, Nishikido M, Usami M, Tsukamoto T and Akaza H: Multicenter phase II trial of S-1 in patients with cytokine-refractory metastatic renal cell carcinoma. J Clin Oncol. 28:5022–5029. 2010. View Article : Google Scholar
19	Miyake M, Fujimoto K, Anai S, Ohnishi S, Nakai Y, Inoue T, Matsumura Y, Tomioka A, Ikeda T, Okajima E, Tanaka N and Hirao Y: Inhibition of heme oxygenase-1 enhances the cytotoxic effect of gemcitabine in urothelial cancer cells. Anticancer Res. 30:2145–2152. 2010.PubMed/NCBI
20	Miyake M, Fujimoto K, Anai S, Ohnishi S, Kuwada M, Nakai Y, Inoue T, Matsumura Y, Tomioka A, Ikeda T, Tanaka N and Hirao Y: Heme oxygenase-1 promotes angiogenesis in urothelial carcinoma of the urinary bladder. Oncol Rep. 25:653–660. 2011. View Article : Google Scholar : PubMed/NCBI
21	Koch I, Depenbrock H, Danhauser-Riedl S, Rastetter JW and Hanauske AR: Interleukin 1 modulates growth of human renal carcinoma cells in vitro. Br J Cancer. 71:794–800. 1995. View Article : Google Scholar : PubMed/NCBI
22	Takeuchi A, Shiota M, Tatsugami K, Yokomizo A, Eto M, Inokuchi J, Kuroiwa K, Kiyoshima K and Naito S: Sorafenib augments cytotoxic effect of S-1 in vitro and in vivo through TS suppression. Cancer Chemother Pharmacol. 68:1557–1564. 2011. View Article : Google Scholar : PubMed/NCBI
23	Naito S, Yokomizo A and Koga H: Mechanisms of drug resistance in chemotherapy for urogenital carcinoma. Int J Urol. 6:427–439. 1999. View Article : Google Scholar : PubMed/NCBI
24	Shibayama Y, Nakano K, Maeda H, Taguchi M, Ikeda R, Sugawara M, Iseki K, Takeda Y and Yamada K: Multidrug resistance protein 2 implicates anticancer drug-resistance to sorafenib. Biol Pharm Bull. 34:433–435. 2011. View Article : Google Scholar : PubMed/NCBI
25	Wang EJ and Johnson WW: The farnesyl protein transferase inhibitor lonafarnib (SCH66336) is an inhibitor of multidrug resistance proteins 1 and 2. Chemotherapy. 49:303–308. 2003. View Article : Google Scholar : PubMed/NCBI